c-Met as a prognostic marker in gastric cancer: A systematic review and meta-analysis

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Yu, Shan ^a   Yu, Yiyi ^a   Zhao, Naiqing ^a   Cui, Jianlan ^a   Li, Wei ^a   Liu, Tianshu ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; SCATTER FACTOR RECEPTOR;

ASIAN; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL HETEROGENEITY; ETHNICITY; HUMAN; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER; SYSTEMATIC REVIEW;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84892394160     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079137     Document Type: Review

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Ajani JA (2008) Gastroesophageal cancers: Progress and problems. J Natl Compr Canc Netw 6(9): 813-814. PubMed: 18998257.
3. Goscinski MA, Larsen SG, Warloe T, Stoldt S, Nesland JM et al. (2009) Adenocarcinomas on the rise-does it influence survival from oesophageal cancer? Scand J Surg 98(4): 214-220. PubMed: 20218417.
4. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh JS (2001) Overexpression of the c-met protooncogene in human gastric carcinoma: Correlation to clinical features. Acta Oncol 40(5): 638-643. doi:10.1080/028418601750444204. PubMed: 11669338.
5. Wu CW, Li AF, Chi CW, Chung WW, Liu TY et al. (1998) Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5(4): 817-822. PubMed: 9625824.
6. Inoue T, Kataoka H, Goto K, Nagaike K, Igami K et al. (2004) Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci 95(10): 803-808. doi:10.1111/j.1349-7006.2004.tb02185.x. PubMed: 15504247.
7. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M et al. (1999) The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 85(9): 1894-1902. doi:10.1002/(SICI) 1097-0142(19990501)85:9〈1894::AID-CNCR3〉 3.0.CO;2-J. PubMed: 10223227.
8. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB et al. (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J of clininical Oncology 29(36): 4803-4810. doi:10.1200/JCO.2011.35.4928. PubMed: 22042947.
9. Kuniyasu H, Yasui W, Kitadai Y, Yokozaki H, Ito H et al. (1992) Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun 189(1): 227-232. doi:10.1016/0006-291X(92)91548-5. PubMed: 1333188.
10. Amemiya H, Kono K, Itakura J, Tang RF, Takahashi A et al. (2002) c-Met expression in gastric cancer with liver metastasis. Oncology 63(3): 286-296. doi:10.1159/000065477. PubMed: 12381909.
11. Retterspitz MF, Mönig SP, Schreckenberg S, Schneider PM, Hölscher AH et al. (2010) Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res 30(11): 4635-4641. PubMed: 21115917.
12. Tang Z, Zhao M, Ji J, Yang G, Hu F et al. (2004) Overexpression of gastrin and c-met protein involved in human gastric carcinomas and intestinal metaplasia. Oncol Rep 11(2): 333-339. PubMed: 14719064.
13. Conrotto P, Valdembri D, Corso S, Serini G, Tamagnone L et al. (2005) Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 105(11): 4321-4329. doi:10.1182/blood-2004-07-2885. PubMed: 15632204.
14. Yi S, Tsao MS (2000) Activation of hepatocyte growth factor-met autocrine loop enhances tumorigenicity in a human lung adenocarcinoma cell line. Neoplasia 2(3): 226-234. PubMed: 10935508.
15. Kelly S, Oliner, Tang Rui, Anderson Abraham, Lan Yun, Timothy Iveson et al. (2012) Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 30(suppl; abstr: 4005).
16. Parmar MKB, Torri V, Stewart L (1998) Extracting summary statistics to perform Meta-analyses of the published literature for survival endpoints. Statist Med 17(24): 2815-2834. doi:10.1002/(SICI)1097-0258(19981230)17:24. PubMed: 9921604.
17. Wu CW, Li AF, Chi CW, Chung WW, Liu TY et al. (1998) Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 5(4): 817-822. PubMed: 9625824.
18. Yonemura Y, Nojima N, Kaji M, Kawamura T, Fushida S et al. (1997) E-cadherin and c-met expression as a prognostic factor in gastric cancer. Oncol Rep 4(4): 743-748. PubMed: 21590132.
19. Shi J, Yao D, Liu W, Wang N, Lv H et al. (2012). nt J Molecular Sciences Frequent Gene Amplif Predicts Poor Prognosis Gastric Cancer 13(4): 4714-4726
20. Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E et al. (2011) Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 29(36): 4789-4795. doi:10.1200/JCO.2011.36.7706. PubMed: 22042954.
21. Zhao J, Zhang X, Xin Y (2011) Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas. Histol Histopathol 26(9): 1111-1120. PubMed: 21751142.
22. Lee J, Seo JW, Jun HJ, Ki CS, Park SH et al. (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25(6): 1517-1524. PubMed: 21424128.
23. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E et al. (2008) The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19(6): 1477-1483. PubMed: 18497953.
24. Han SU, Lee HY, Lee JH, Kim WH, Nam H et al. (2005) Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann Surg 242(5): 676-683. doi:10.1097/01.sla.0000186171.85804.fe. PubMed: 16244541.
25. Kubicka S, Claas C, Staab S, Kühnel F, Zender L et al. (2002) p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. Dig Dis Sci 47(1): 114-121. doi:10.1023/A:1013275706401. PubMed: 11837710.
26. Tsugawa K, Yonemura Y, Hirono Y, Fushida S, Kaji M et al. (1998) Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology 55(5): 475-481. doi:10.1159/000011898. PubMed: 9732228.
27. Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S et al. (1998) The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer 82(11): 2112-2122. doi:10.1002/(SICI)1097-0142(19980601)82:11. PubMed: 9610690.
28. Li Y, Chen CQ, He YL, Cai SR, Yang DJ et al. (2012) Abnormal Expression of E-Cadherin in Tumor Cells is Associated With Poor Prognosis of Gastric Carcinoma. J Surg Oncol 106(3): 304-310. doi:10.1002/jso.23008. PubMed: 22231933.
29. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK et al. (2012) MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 107(2): 325-333. doi:10.1038/bjc.2012. 237. PubMed: 22644302.
30. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E et al. (2011) RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol&thrapy 12(1): 9-46. doi:10.4161/cbt.12.1.15747. PubMed: 21543897.
31. Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H et al. (2012) Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 130(12): 2912-2921. doi:10.1002/ijc.26330. PubMed: 21796631.
32. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M et al. (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology Jun 52(7): 797-805. doi:10.1111/j.1365-2559. 2008.03028.x. PubMed: 18422971.
33. Gill S, Shah A, Le N, Cook EF, Yoshida EM (2003) Asian ethnicityrelated differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol 21(11): 2070-2076. doi:10.1200/JCO.2003. 11.054. PubMed: 12775731.
34. Kim J, Sun CL, Mailey B, Prendergast C, Artinyan A (2010) Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Ann Oncol 21(1): 152-160. doi:10.1093/annonc/mdp290. PubMed: 19622590.